MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis

Andrej Spec, John Pullman, George R. Thompson, William G. Powderly, Ellis H. Tobin, Jose Vazquez, Stephen A. Wring, David Angulo, Silvia Helou, Peter G. Pappas

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'MSG-10: A Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science